ALMR · XBRL financial data
Alamar Biosciences financial statements, every quarter
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Revenue from contracts with customers | 26,035 | 29,427 |
| Cost of revenue | 11,578 | 11,709 |
| Gross profit | 14,457 | 17,718 |
| Research and development | 13,017 | 13,817 |
| Selling, general and administrative | 13,787 | 17,433 |
| Total operating expenses | 26,804 | 31,250 |
| Other operating income (expense) | (236) | (34) |
| Operating income (loss) | (12,347) | (13,532) |
| Income tax expense (benefit) | 464 | (93) |
| Net income (loss) | (21,325) | (13,199) |
| Earnings per share, basic USD per share | (1.74) | (0.22) |
| Earnings per share, diluted USD per share | (1.74) | (0.22) |
| Weighted average shares, basic thousands of shares | 12,260 | 58,665 |
| Weighted average shares, diluted thousands of shares | 12,260 | 58,665 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Cash and cash equivalents | 64,586 | 132,969 |
| Short-term investments | 0 | 117,083 |
| Accounts receivable | 19,524 | 20,344 |
| Inventory | 39,931 | 45,409 |
| Prepaid and other current assets | 17,432 | 15,577 |
| Total current assets | 141,473 | 331,382 |
| Property and equipment, net | 10,472 | 13,358 |
| Right-of-use asset | 25,671 | 35,798 |
| Total assets | 186,451 | 390,975 |
| Accounts payable | 5,635 | 13,790 |
| Total current liabilities | 24,048 | 27,960 |
| Lease liability, non-current | 28,979 | 39,182 |
| Total liabilities | 129,526 | 78,118 |
| Accumulated deficit | (190,100) | (203,299) |
| Total stockholders' equity | (178,071) | 312,857 |
| Total liabilities and equity | 186,451 | 390,975 |
| Common shares outstanding (cover page) thousands of shares | 69,311 | 69,393 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Net income (loss) | (21,325) | (13,199) |
| Stock-based compensation | 1,467 | 3,280* |
| Net cash from operating activities | (20,347) | (11,322)* |
| Purchases of property and equipment | 600 | 3,642* |
| Net cash from investing activities | (778) | (120,796)* |
| Net cash from financing activities | 55,761 | 201,841* |
| Net change in cash | 34,584 | 69,730* |
Compare with peers
SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Alamar Biosciences | 121,532 | 33,545 | not reported | 69.5M | — | 10-QSep 30, 2026 |
| Owlet | 30,948 | 33,865 | (92)* | 29.2M | 336.4 quarters | 10-QJun 30, 2026 |
| Quanterix | 44,169 | 32,906 | (5,119)* | 47.3M | 18.3 quarters | 10-QJun 30, 2026 |
| Intest | 22,102 | 35,313 | not reported | 12.8M | — | 10-QJun 30, 2026 |
| Sypris Solutions | not reported | 30,341 | 1,863* | 23.0M | — | 10-QJul 5, 2026 |
| Pacific Biosciences of California | 61,003 | 39,007 | (35,583)* | 310.8M | 6.7 quarters | 10-QJun 30, 2026 |
| Crawford United | 1,923 | not reported | 5,706* | not reported | — | 10-QSep 30, 2025 |
| Hurco Companies | 52,087 | 47,289 | 3,805 | 6.5M | — | 10-QJul 31, 2026 |
| Frequency Electronics | 61,407 | 23,451 | 2,622 | 11.3M | — | 10-QJul 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.